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P-Cadherin Overexpression Is an Indicator of Clinical Outcome
in Invasive Breast Carcinomas and Is Associatedwith
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Abstract Purpose:P-cadherinoverexpressionhas been reported inbreast carcinomas, where it was asso-
ciated with proliferative high-grade histological tumors. This study aimed to analyze P-cadherin
expression in invasive breast cancer and to correlate it with tumor markers, pathologic features,
and patient survival. Another purpose was to evaluate the P-cadherin promoter methylation
pattern as themolecular mechanismunderlying this gene regulation.
Experimental Design:Using a series of invasive breast carcinomas, P-cadherin expressionwas
evaluated and correlated with histologic grade, estrogen receptor, MIB-1, and p53 and c-erbB-2
expression. In order to assess whether P-cadherin expression was associated with changes in
CDH3 promoter methylation, we studied the methylation status of a gene 5V-flanking region in
these same carcinomas.This analysis was also done for normal tissue and for a breast cancer cell
line treatedwith a demethylating agent.
Results:P-cadherinexpression showeda strongcorrelationwithhighhistologic grade, increased
proliferation, c-erbB-2 and p53 expression, lack of estrogen receptor, and poor patient survival.
This overexpressioncanbe regulatedbygenepromotermethylationbecause the5-Aza-2V-deoxy-
cytidine treatment ofMCF-7/AZ cells increased P-cadherinmRNAandprotein levels. Additionally,
we found that 71% of P-cadherin-negative cases showed promotermethylation, whereas 65% of
positive ones were unmethylated (P = 0.005). The normal P-cadherin-negative breast epithelial
cells showed consistentCDH3 promoter methylation.
Conclusions: P-cadherin expressionwas strongly associated with tumor aggressiveness, being
a good indicator of clinical outcome. Moreover, the aberrant expression of P-cadherin in breast
cancer might be regulated by gene promoter hypomethylation.
Cadherins are cell-cell adhesion glycoproteins that form
calcium-dependent intercellular junctions and play an essen-
tial role in morphogenesis and in the development and
maintenance of adult tissues and organs (1). During
embryogenesis, the cell expression of specific cadherins
results in homophilic interactions that are critical in the
process of cell sorting and tissue stratification (2 – 4).
Alterations in these cellular attachments play an important
role in cell destabilization and may modify the carefully
regulated differentiation process of the epithelial structures
(5, 6). For this reason, the functional loss or overexpression
of cadherins and the molecular mechanisms underlying the
control of the genes codifying these proteins have been
implicated in carcinogenesis (7).
The cadherin family is subdivided into various subfamilies,
including the classical E-, P-, and N-cadherins, each demon-
strating a specific tissue distribution (8). Although E-cadherin is
expressed in all epithelial tissues, the expression of P-cadherin
is only restricted to the basal or lower layers of stratified
epithelia, including prostate and skin, and also to the breast
myoepithelial cells (6, 9). This unique distribution of
P-cadherin suggests that, in addition to maintaining cellular
adhesion, this molecule may also have other unknown
functions, which can be important in cell differentiation and
proliferation (5, 6).
Up-regulation of P-cadherin has been shown in several
lesions, including breast cancer, in which there is usually down-
regulation of E-cadherin (10). Breast carcinomas show aberrant
P-cadherin expression in f30% of the cases and has been
reported as a prognostic marker of poor outcome in patients
(11, 12). The differential pattern of P-cadherin expression in
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breast cancer development, coupled with its possible prognos-
tic value, prompted us to investigate its expression in a series of
invasive breast carcinomas.
Furthermore, we have previously found that P-cadherin
aberrant expression results from a lack of estrogen receptor-a
(ER-a) signaling and induces in vitro cell invasion in a
juxtamembrane domain-dependent manner (13). Additionally,
based on the fact that the 5V-flanking region (Genbank no.
X95824) of the P-cadherin gene (CDH3) has been character-
ized as a CpG island (14), we thought that promoter
methylation could be a putative molecular mechanism
responsible for its transcriptional regulation.
This hypothesis is also supported by the fact that the same
mechanism of regulation was shown for the E-cadherin gene.
Aberrant methylation across the promoter region of this gene
results in a selective inactivation of its transcription (15, 16).
E- and P-cadherin genes exhibit a similar genomic organization,
both containing 16 exons and a similar promoter region (17).
The localization of the human P-cadherin gene is at 32 kb
upstream of the human E-cadherin gene, also mapping to
chromosome 16q22.1, showing the evolutionary conservation
of the tandem arrangement of two genes encoding cell
adhesion molecules, suggesting that the close proximity of
these genes may be important for their regulation (18).
The 5V-flanking region of the E-cadherin gene has been
sequenced and found to be extremely CG-enriched, meeting the
criteria for a ‘‘CpG island’’ (19, 20). Methylation of E-cadherin
has been shown in breast cancer and in some other cancers and
cell lines (16, 21–24), although this functional block of
E-cadherin expression can be removed with exposure of cell
lines to demethylating agents in vitro (25–27). Additional
factors regarding the E-cadherin gene, which seem important to
transcriptional regulation, include a palindromic sequence
E-pal (where transcriptional repressors as Snail and Slug bind)
and a Sp-1 binding site (19).
In contrast, the comparison of the 5V-flanking sequence of the
human P-cadherin gene with the one for E-cadherin shows no
homology for this palindromic sequence E-pal (17). In the
P-cadherin promoter, there is conservation of a CAAT box, with
no TATA box, and three E boxes (helix-loop-helix binding
motif). A putative Sp-1 binding site is also conserved (14). An
Alu repeat is present f700 bp upstream from the translation
start site, and analogous to the human E-cadherin sequence,
shows a CG-rich region characteristic of a CpG island (14).
Genes that show a CpG island within their promoter region
are normally regulated by methylation. Few studies describing
P-cadherin promoter methylation status have been published
thus far and, to the best of our knowledge, none have been
done in human breast cancer specimens. However, cytosine
methylation of this region was described in P-cadherin-
nonexpressing prostate cancer cell lines (LNCaP, TSU-PR1,
and DuPRO) but not in cell lines expressing this gene (PC3,
DU145, and PPC1; refs. 14, 19). Simultaneously, a recent study
describing epigenetic silencing of E- and P-cadherin gene
expression in human melanoma cell lines was reported, in
which methylation-specific PCR analysis revealed that
P-cadherin seems to be silenced by methylation events (28).
Although these studies point to cytosine methylation as a
possible mechanism of P-cadherin expression regulation,
Jarrard et al. claim that other mechanisms should be able to
regulate the consistent loss of P-cadherin expression in in vivo
prostate cancer specimens. In contrast with breast cancer
models, these authors found that P-cadherin is restricted to
basal epithelial cells in normal prostate samples, but is down-
regulated in prostatic intraepithelial neoplasia and is absent in
all prostate cancer specimens analyzed. Additionally, the lack of
expression was not associated with methylation of the
P-cadherin promoter (14).
Based on all these results, we decided to evaluate if the
promoter methylation could be the molecular mechanism
responsible for the transcription regulation of the CDH3 gene,
using a series of invasive breast carcinomas. These results were
compared with normal breast tissue, and confirmed in a breast
cancer cell line treated with a demethylating agent.
Materials andMethods
Breast tumor samples
Formalin-fixed paraffin-embedded blocks of 150 invasive breast
carcinomas were retrieved from the histopathology files at the
Department of Pathology, Hospital Xeral Cı´es, Vigo, Spain, selected
from a cohort of patients with follow-up information. From all cases,
we analyzed the available relevant data, including age, tumor size,
mitotic index, axillary metastasis, tumor grade, ER-a status, MIB-1,
c-erbB-2, and p53 expression. The mean age of the patients at diagnosis
was 56 years (range, 28-82 years old). The size of the tumors ranged
from 1 to 10 cm (mean, 2.8 F 1.5 cm). ER-a was evaluated in 150
tumors, where 100 cases were positive. MIB-1 expression was assessed
in 147 cases, 70 with <15% of positive cells and 77 with >15% of
positive cells. C-erbB-2 expression was analyzed in 139 cases and p53
expression in 145 cases, 34 cases were positive for c-erbB-2 and 66 were
positive for p53. As a measure of prognosis, we analyzed the clinical
data concerning disease-free survival, defined as the time from
diagnosis to first recurrence or last contact, and the overall survival,
defined as the time from diagnosis to death by breast cancer or last
contact.
Immunohistochemistry
Immunohistochemical studies of representative sections were carried
out using standard methods. Sections cut 2 Am thick were mounted on
gelatin (Merck, Merck KgaA, Darmstadt, Germany) and chromium (III)
potassium sulfate 12-hydrate–coated slides (Merck), dried overnight at
37jC, deparaffinized with xylene and hydrated. An antigen retrieval
method was carried out by microwave treatment, in a 0.05% detergent
solution for E- and N-cadherin antibodies (10 minutes), and with a
10 mmol/L citrate buffer, pH 6.0 (DAKO Corporation, Carpinteria, CA)
for P-cadherin antibody (30 minutes). Endogenous peroxidase was
blocked with 3% hydrogen peroxide in methanol for 10 minutes.
Sections were submitted to protein blockage with a specific serum
(Ultravision block, LabVision Corporation, Fremont, CA) and incubated
with the monoclonal primary antibody for 30 minutes at room
temperature (E-cadherin, HECD-1, 1:200, Zymed Laboratory, San
Francisco, CA; P-cadherin, clone 56, 1:50, Transduction Laboratories,
Lexington, KY; and N-cadherin, clone 3B9, 1:400, Zymed Laboratory).
The other steps of immunohistochemical staining were done using
standard protocols on an automated LabVision Autostainer (LabVision
Corporation), with a specific kit based on streptavidin-biotin-peroxidase
method. Subsequently, the sections were counterstained with Mayer’s
hematoxylin, dehydrated, cleared, and mounted.
Positive and negative controls were included with each batch of
staining to ensure consistency between consecutive runs. Paraffin
sections of normal skin tissue were used as positive controls for E-
cadherin, normal breast tissue was used for P-cadherin, and cardiac
muscle was used for N-cadherin. Immunohistochemical results were
not assessed in some cases (49 for E-cadherin, 3 for P-cadherin, and
8 for N-cadherin) because there was no more tumor material available.
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Quantification of immunostaining
All tumors presenting an unequivocal membranous staining for
cadherin in at least 10% of the neoplastic cells were scored as positive.
Cells with cytoplasmic expression alone were not considered. The
assessment of immunohistochemical results was based on a semiquan-
titative evaluation, which did not include staining intensity, as
previously reported (29).
Cell culture and treatments
The human MCF-7/AZ breast cancer cell line was obtained from Prof.
Marc Mareel (Laboratory of Experimental Cancerology, Ghent Univer-
sity, Belgium) and routinely maintained at 37jC and 10% CO2, in 50%
DMEM/50% Ham’s F12 media (Invitrogen, Merelbeke, Belgium),
supplemented with 10% heat-inactivated fetal bovine serum (Invitro-
gen), 100 IU/mL penicillin, and 100 g/mL streptomycin (Invitrogen).
These cells were incubated during 5 days with 2.5 Amol/L of 5-Aza-
2V-deoxycytidine (Sigma Chemical Co., St. Louis, MO), which reduces
the level of 5-methylcytosine in DNA, or just with DMSO (which was
the vehicle of this drug) for use as a control. After 5 days, RNA and
protein cell lysates were isolated from these cells.
Reverse transcription-PCR analysis
Reverse transcription-PCR experiments were done using total RNA,
which was extracted from f5  106 cells using the Qiagen RNeasy kit
(Qiagen, Chatsworth, CA). One microgram of total RNA was reverse-
transcribed with oligo(dT) primers using the Qiagen RT kit (Qiagen)
according to the manufacturer’s instructions. P-cadherin cDNA was
amplified using the sense primer 5V-ACGAAGACACAAGAGAGATTGG
and the antisense primer 5V-CGATGATGGAGATGTTCATGG, in order to
generate a 287-bp product. PCRs were done in 250 ng template cDNA
using the Qiagen Taq PCR kit (Qiagen) according to the manufacturer’s
instructions. Reactions were done in a Minicycler (Biozym, Landgraaf,
the Netherlands) with an initial denaturation at 94jC for 3 minutes; 20,
30, or 35 cycles of 94jC for 50 seconds (denaturation), 55jC for 50
seconds (annealing), and 72jC for 1 minute (elongation), followed by
a final extension at 72jC for 10 minutes.
Western blot analysis
All lysates were made of cells f90% confluence, which were washed
thrice with PBS. Cells were lysed with PBS containing 1% Triton X-100,
1% Nonidet P-40 (Sigma), and the following protease inhibitors:
aprotinin (10 Ag/mL), leupeptin (10 Ag/mL; ICN Biomedicals, Costa
Mesa, CA), phenylmethylsulfonyl fluoride (1.72 mmol/L), NaF (100
Amol/L), NaVO3 (500 Amol/L), and Na4P2O7 (500 Ag/mL; Sigma). After
clearing the lysates, protein concentration was determined using the Rc
Dc protein assay (BioRad, Richmond, CA), and samples were prepared
such that equal amounts of protein were to be loaded. Sample buffer
(Laemmli) with 5% 2-mercaptoethanol and 0.012% bromophenol blue
was added, followed by boiling for 5 minutes and separation of proteins
by gel electrophoresis on an 8% polyacrylamide gel and transfer onto a
nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway,
NJ). Quenching and immunostaining of the blots were done in 5%
nonfat dry milk in PBS containing 0.5% Tween 20. The membranes were
quenched for 1 hour, incubated with primary antibody for P-cadherin
(clone 56, 1:500, Transduction Laboratories) for 1 hour, washed
four times for 10 minutes, incubated with horseradish peroxidase–
conjugated secondary antibody for 45 minutes, and washed six times for
10 minutes. Detection was done using enhanced chemiluminescence
reagent (Amersham Pharmacia Biotech) as a substrate.
Laser-assisted tissue microdissection
To analyze the methylation pattern in normal epithelia, five frozen
normal breast tissues were selected from the archive of the Department
of Pathology, Hospital Sa˜o Joa˜o, Porto, Portugal. These frozen samples
were included in ornithine carbamyl transferase solution (Bright,
Huntingdon, England) and sections 10 Am thick were placed in specific
slides for laser microdissection. The slides were stained with H&E and
visualized in a Laser Microdissector Microscope (PALM, Bernried,
Germany). Breast normal glandular epithelia were identified in the
sections and only prominent epithelial cells were selected for
microdissection (Fig. 1A). In all cases, >10,000 epithelial cells were
cautiously laser-cut and laser pressure–catapulted for a specific vial
(Fig. 1B), from which DNA extraction was done according to Qiagen
protocols for DNA extraction from laser tissue microdissection.
Methylation-specific PCR analysis
In order to optimize the methylation-specific PCR technique, we
used genomic DNA extracted from nine frozen breast tumor tissues
retrieved from the Portuguese Oncology Institute of Coimbra (IPOFG-
CROC, Portugal). The tumor tissues were macerated and genomic DNA
extraction was done according to the standard protocol for human
tissues—Genomic DNA from Tissue Kit (NucleoSpin Tissue, Macherey-
Nagel, GmbH & Co., KG, Du¨ren, Germany). Genomic DNA (200 ng/
AL) was converted by bisulfite treatment as described below. Because we
studied P-cadherin protein expression in these frozen tumor cases, these
methylation-specific PCR results were also considered for statistical
analysis, together with 55 cases from the series of paraffin-embedded
samples, where tumor material was still available to perform DNA
extraction.
DNA extraction
Fifty-five paraffin-embedded samples were cut to 10-Am-thick sections
and, after identification of the tumor areas of interest, these were carefully
microdissected. The samples were then placed into microcentrifuge tubes
with a freshly prepared lysis buffer/proteinase K mixture, and incubated
overnight at 56jC until complete lysis of the fragments. The DNA
extraction was done according to the same standard protocol for human
tissues previously referred to. DNA from all 64 samples (55 paraffin-
embedded and 9 frozen cases) was quantified, and wild-type DNA from
each case was amplified using P-cadherin-specific primers. Genomic
blood DNA was used as wild-type positive control (Fig. 2A).
Methylation analysis
Bisulfite treatment. Sodium bisulfite conversion of P-cadherin 5V
CpG island was done in 3 Ag of genomic DNA from the total 64 tumor
cases. This same treatment was applied to DNA extracted from the five
normal breast tissues that were laser-microdissected. Briefly, and based
on the standard protocol described elsewhere (30), DNA was denatured
by incubation with NaOH (final concentration, 0.2 mol/L), for 20
minutes at 50jC. To function as a carrier, 1 Ag of salmon sperm DNA
(Stratagene, La Jolla, CA) was mixed with the initial human DNA. A
freshly made sodium bisulfite solution [2.5 mol/L sodium bisulfite
(Sigma), 125 mmol/L hydroquinone (Sigma), and NaOH 2 mol/L (pH
5.0)] was added to the DNA sample, in order to convert the
unmethylated cytosines to uracils. This conversion allows the distinction
between methylated and unmethylated DNA. After 3 hours of
incubation in the dark at 70jC, converted DNA was purified, using a
commercial Wizard DNA purification resin, as described by the
manufacturer (Promega Corporation, Madison, WI). Finally, the
purified DNA was eluted into 45 AL of preheated (80jC) water.
Fig. 1. Illustration of a normal mammary duct selected for laser tissue
microdissection: A, only clearly identifiable epithelial cells layer were cautiously
selected. B, the epithelial cell clusters were laser-cut and catapulted for a
special vial for DNA extraction.
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Modification was completed by NaOH treatment (final concentration,
0.3 mol/L) for 10 minutes at room temperature, followed by
neutralization reaction with 75 AL of ammonium acetate 6 mol/L.
DNA precipitation was done by adding 2 AL of glycogen (5 mg/mL; MBI
Fermentas), and after pellet washing with 70% ethanol, DNA was dried,
resuspended in 40 AL of water and stored at 20jC.
Methylation-specific PCR analysis. After the bisulfite treatment, all
samples were amplified by PCR. For a final volume of 25 AL of PCR
reaction mix, 400 ng of bisulfite-modified DNA was added to the
PCR mix containing 1 PCR buffer [16.6 mmol/L ammonium sulfate,
67 mmol/L Tris (pH 8.8), 6.7 mmol/L MgCl2, and 10 mmol/L
2-mercaptoethanol], deoxynucleotide triphosphates (each at 1 mmol/L),
0.6 Amol/L primers, 2% DMSO and 1 unit Platinum Taq DNA
polymerase (Life Technologies, Inc., Rockville, MD). The gene-specific
primer sequences for both methylated and unmethylated P-cadherin
promoter were, respectively: P-cad-M (sense 5V-GGCGGGATT-
TCGTGGCGT; antisense 5V-ATAAAACAACTACCGCGACG); P-cad-U
(sense 5V-GGTGGGATTTTGTGGTGTTG; antisense 5V-ATAAAACAAC-
TACCACAACAACA). The annealing temperature was 55jC, generating
a 140-bp product. Reactions were hot-started at 95jC for 5 minutes and
PCR amplification was carried out in a thermocycler for 38 cycles (30
seconds at 95jC, 30 seconds at 55jC, the annealing temperature, and 45
seconds at 72jC). A final extension was done at 72jC for 10 minutes.
Negative controls, without DNA, were done for all sets of PCRs. Each PCR
product was directly loaded into a nondenaturing 6% polyacrylamide gel,
and stained with silver nitrate. As a positive methylation control, we used
blood DNA treated with CpG methylase M.SssI (BioLabs Inc., New
England; in vitro DNA), and blood bisulfite-treated DNA was used as a
positive unmethylated control (Fig. 2B). Genomic DNA was also
obtained from human prostate cancer cell lines, for use as additional
positive methylation controls: LNCaP, which present methylation within
the CDH3 promoter, and PC3, which express detectable P-cadherin and
are unmethylated at CDH3 promoter (ref. 14; Fig. 2B).
As already mentioned, we also did PCR amplification for P-cadherin
promoter wild-type sequence, and the primers used were: P-cad-W (sense
5V-GGGGCGGGACCTCGTGGCGC; antisense 5V-GTGAAGCAG-
CTGCCGCGACG). The annealing temperature was 67jC, generating a
142-bp product. Human DNA extracted from blood leukocytes was used
as positive controls. For a final volume of 30 AL of PCR reaction mix,
200 ng of DNA was added to 1 PCR buffer [500 mmol/L KCl,
100 mmol/L Tris (pH 8.8), and 0.8% NP40], deoxynucleotide
triphosphates (each at 0.2 mmol/L), 0.3 Amol/L primers, and 1 unit
of Taq DNA polymerase (Amersham Pharmacia Biotech). The PCR
amplification was carried out using the following conditions: 1 cycle
at 95jC for 5 minutes, and 35 cycles at 95jC for 30 seconds, followed
by 67jC (specific annealing temperature) for 30 seconds and 72jC for
45 seconds. Additionally, a final extension at 72jC for 10 minutes was
done. Negative controls without DNA were used for all sets of PCRs.
As expected, P-cadherin wild-type primers did not recognize the
promoter site of bisulfite-transformed DNA (Fig. 2A). All the ampli-
fied products were directly loaded and stained as described above.
In order to classify the methylation status of the cases that were
studied, the ones showing only methylated alleles were considered
methylated (M; or with complete methylation), and the ones with only
unmethylated alleles were considered unmethylated (U; or with
complete demethylation). The cases that showed partial methylation,
which means the presence of both methylated and unmethylated
alleles, were also considered methylated (M), based on previous reports
describing methylation-specific PCR analysis (24, 31, 32).
Statistical analysis
For statistical analysis, contingency tables and m2 test were done to
estimate the relationship between staining patterns of the different
cadherins and several of the factors analyzed, such as tumor grade,
lymph node metastasis, vascular invasion, ER-a, MIB-1, c-erbB-2 and
Fig. 2. Wild-type and methylation control patterns of the analyzed P-cadherin
promoter region (W, wild-type; M, methylated; U, unmethylated): A, wild-type
pattern of genomic DNA untreated and treated with bisulfite (DNA-T). As
expected, P-cadherin wild-type primers do not recognize the promoter site of
bisulfite-transformed DNA. B, on the left, the blood DNA treated with CpG
methylase M.SssI (in vitro DNA) was only amplified with P-cadherin primers
specifically designed for methylated promoter region after the bisulfite treatment.
Bisulfite-treated DNA from blood was used as a positive control for the
unmethylated promoter region. On the right, bisulfite-treated DNA from LnCap
and PC3 cell lines were also used as P-cadherin methylation and unmethylation
positive controls, respectively.
Fig. 3. A, strongmembranous and
cytoplasmic expression of P-cadherin in a
high-grade invasive breast carcinoma. H&E,
400. B, correlation between P-, E-, and
N-cadherin expression and tumor histologic
grade.C andD, Kaplan-Meier curves
showing probability of disease-free survival
and overall-survival, respectively, for patients
with P-cadherin-positive tumors versus
patients with P-cadherin-negative tumors
(log-rank test).
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p53 expression, and CDH3 methylation status. ANOVA was used to
investigate differences in tumor size and mitotic index. Two values
were considered significantly different when P < 0.05. Univariate
survival curves were estimated using the method of Kaplan-Meier and
compared using the log-rank test. Statistical analyses were carried out
using StatView 5.0 Software (SAS Institute Inc., Cary, NC).
Results
Cadherin expression and correlation with biologi-
cal markers
From the 150 cases of the studied series, 149 were graded in
accordance with the modified criteria of Bloom and Richardson
(14, 33): 21 were classified as grade I (14.1%), 44 as grade II
(29.5%), and 84 as grade III (56.4%) tumors.
P-cadherin immunoreactivity was absent in 101 (68.7%)
primary breast cancers analyzed and aberrantly expressed in 46
cases (31.3%). Distribution of P-cadherin in tumor cells
showed membranous staining frequently associated with
cytoplasmic expression (Fig. 3A). P-cadherin expression was
always found in myoepithelial cells from normal ducts/acini
and from ducts containing in situ carcinoma, but not in acinar
or ductal normal epithelial cells.
P-cadherin expression showed a statistically significant corre-
lation with histologic grade, because this protein was essentially
present in high-grade tumors (36 of 46; 78.3%), whereas grade I
cases were almost all negative (P = 0.0021; Fig. 3B).
Statistical analysis revealed an inverse correlation between
P-cadherin expression and ER-a status: 80.2% of P-cadherin-
negative cases were ER-a-positive. The m2 test showed that this
difference was statistically significant (P < 0.0001; Table 1). The
correlation between P-cadherin and MIB-1, and c-erbB-2 and
p53 expressions, was also evaluated: the majority of P-cadherin-
positive cases were highly proliferative (P = 0.0002), and
significantly related to c-erbB-2 (P = 0.0036) and p53
expression (P = 0.0064; Table 1). Additionally, an important
association was observed with high mitotic index (P = 0.0003,
data not shown). No significant correlation was found between
P-cadherin expression and tumor size, axillary lymph node
metastasis, and angiogenesis. Although invasive ductal carci-
nomas and medullary carcinomas were frequently P-cadherin-
positive, a statistically significant difference with the tumor
histologic type was not reached.
Concerning E-cadherin, half of the studied cases were
negative (52 of 101; 51.5%), showing a clear decrease of
membranous staining in the neoplastic epithelial cells.
N-cadherin was only found in 2.11% (3 of 142) of the tumors,
and its expression was restricted to a small population of cells
with a faint membranous staining, and with cytoplasmic
expression. No correlation was found between the expression
of these two cadherins and any of other tumor parameters
studied here (Table 1; Fig. 3B), and there were also no
significant associations between the expression of cadherins.
Cadherin expression and survival analysis
The mean follow-up time was 113 F 53 months (range,
1-176 months). There were 12 local recurrences after diagnosis,
Table 1. Correlation between P-, E-, and N-cadherin expression and ER-a, MIB-1, c-erbB-2, and p53-positive
expression
P-cad + P-cad  P E-cad + E-cad  P N-cad + N-cad  P
ER-a 34.8% (16 of 46) 80.2% (81of101) <0.0001 75.5% (37 of 49) 61.53% (32 of 52) 0.1315 100% (3 of 3) 68.3% (95 of139) 0.2408
MIB-1 76% (35 of 46) 42.9% (42 of 98) 0.0002 46.8% (22 of 47) 54.9% (28 of 51) 0.4233 33.3% (1of 3) 52.2% (71of136) 0.5176
c-erbB-2 41.5% (17 of 41) 17.9% (17 of 95) 0.0036 32.56% (14 of 43) 20% (10 of 50) 0.1676 33.3% (1of 3) 23.4% (30 of128) 0.6902
p53 62.2% (28 of 45) 37.8% (37 of 98) 0.0064 39.6% (19 of 48) 50% (25 of 50) 0.3000 50% (1of 2) 46.6% (63 of135) 0.9253
Total 46 101 49 52 3 139
Fig. 4. A, reverse transcription-PCR analysis of P-cadherinmRNA levels after
5-Aza-2V-deoxycytidine treatment of MCF-7/AZ cells for 5 days.The analysis
was done after the indicated number of cycles of PCRamplification. In the presence
of the demethylating agent, the increased P-cad mRNAwas more evident at
the 30-cycle point, during the exponential phase of the PCR reaction. B,
immunoblotting, for P-cadherin analysis, of cell lysates fromMCF-7/AZ cells that
had been treatedwith 5-Aza-2V-deoxycytidine. In comparisonwith the control cells,
there was an increased P-cadherin expression in the MCF-7/Az cells that were
incubated with the demethylating agent. C, methylation-specific PCR results from
the five normal breast tissues, where epithelial cell layers were laser microdissected
from the ducts. All the cases showed completeCDH3 promoter methylation.D,
examples of complete or partial methylation and unmethylation patterns: complete
methylation pattern (cases12 and15), partial methylation pattern (cases13 and18),
and complete unmethylation pattern (cases 8, 9,11,14,16, and17). E, correlation
between P-cadherin expression and themethylation status of the analyzed gene
promoter region.The majority of P-cadherin-negative cases were unmethylated on
this promoter region (P = 0.005).
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45 cases with distant metastasis, and 45 deaths because of
breast cancer in the cohort. Disease-free survival and overall
survival differed significantly between classes of P-cadherin
expression, as revealed in Kaplan-Meier plots. The probabilities
of disease-free and overall survival were significantly lower
for patients with P-cadherin-positive tumors (P = 0.0027 and
P = 0.0237, respectively; Fig. 3C and D). The interval between
diagnosis and local recurrence also showed a slight correlation
with P-cadherin expression: a mean of 35 F 20.15 months
for positive and 73.6 F 32 months for negative tumors
(P = 0.0545). No correlation was found between E- or
N-cadherin expression and disease-free and overall survival.
P-cadherin promoter methylation
MCF-7/AZ cells treated with 5-Aza-2V-deoxycytidine. To
evaluate whether it would be reasonable to test our hypothesis
in a breast cancer series, we treated MCF-7/AZ cells, which
present lower levels of P-cadherin, with the demethylating agent
5-Aza-2V-deoxycytidine (2.5 Amol/L). After 5 days, we harvested
the cells, and we analyzed P-cadherin mRNA and protein levels,
by reverse transcription-PCR and Western blot, respectively.
We observed an increase of both levels, suggesting that
hypomethylation of the promoter accompanies transcriptional
activation of the CDH3 gene in this breast cancer cell line
(Fig. 4A and B).
Normal breast epithelial cells. P-cadherin promoter methyla-
tion was analyzed in five cases of normal breast tissue, from
which only epithelial cells were microdissected. Methylation of
P-cadherin gene was found in all the cases analyzed, because
none of the samples showed the presence of unmethylated
alleles (Fig. 4C). Indeed, these results are highly correlated with
P-cadherin expression because normal breast epithelial cells are
negative for this protein. This evidence supported the hypothe-
sis that the transcriptional inactivation of P-cadherin in such
cells could be regulated by CDH3 promoter methylation.
Invasive breast carcinomas. P-cadherin promoter methyla-
tion was analyzed in 64 cases of invasive carcinomas (Table 2).
Methylation of P-cadherin gene was found in 58% (37 of 64)
of invasive carcinomas, whereas P-cadherin unmethylation was
found in 42% (27 of 64; Fig. 4D; Table 2). When these results
Table 2. CDH3 promoter methylation status and P-cadherin expression in the 64 breast tumor samples studied by
methylation-specific PCRanalysis
Patient no. CDH3 promotermethylation P-cadherin
expression
Patient no. CDH3 promotermethylation P-cadherin
expressionAlleles Status Alleles Status
#1 U/U U positive #72 U/U U negative
#2 U/U U negative #73 M/M M positive
#3 U/U U positive #74 M/M M negative
#4 U/U U negative #75 M/M M negative
#5 U/U U negative #76 M/M M positive
#6 M/U M negative #77 M/M M negative
#7 M/U M negative #78 M/M M negative
#8 U/U U positive #79 M/M M negative
#9 U/U U positive #80 M/M M negative
#11 U/U U positive #81 M/M M positive
#12 M/M M negative #85 M/M M negative
#13 M/U M negative #86 M/M M negative
#14 U/U U positive #111 M/M M negative
#15 M/M M negative #113 M/M M negative
#16 U/U U positive #119 M/M M negative
#17 U/U U positive #125 M/M M positive
#18 M/U M negative #126 M/M M negative
#19 M/U M negative #127 M/M M positive
#20 U/U U positive #132 M/M M negative
#21 M/U M positive #133 M/M M positive
#22 U/U U positive #134 M/M M negative
#24 M/U M negative #135 M/M M negative
#25 U/U U positive #138 M/M M negative
#41 M/M M negative #148 M/M M negative
#42 M/M M positive #151 U/U U positive
#51 U/U U negative #153 U/U U negative
#59 U/U U negative #154 U/U U positive
#60 U/U U negative #155 U/U U negative
#61 U/U U negative #157 M/M M negative
#65 M/M M negative #159 U/U U negative
#66 U/U U positive #160 U/U U negative
#67 M/M M negative #161 U/U U positive
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were correlated with P-cadherin expression, a statistically
significant association was found between these variables:
71% of P-cadherin-negative cases were methylated, whereas
65% of positive cases were unmethylated (P = 0.005; Fig. 4E;
Table 2). Interestingly, six out of seven cases showing partial
methylation (with both methylated and unmethylated alleles)
were negative for P-cadherin expression, reinforcing the
correlation that was observed. Thus, the transcriptional control
of P-cadherin in human breast cancer might be associated with
changes of CDH3 CpG island promoter methylation.
Discussion
Over the last 5 years, research on breast cancer has
suggested the use of many new prognostic markers. Some of
these markers could raise questions, not only about divergent
phenotypes, but also about different histogenesis. One of
these examples is P-cadherin, which has been identified as a
possible valuable indicator of poor prognosis in breast cancer
patients (12). In this study, confirming the results obtained by
others (11, 12, 29, 34), P-cadherin was indeed significantly
expressed in high-grade, ER-a-negative, and highly prolifera-
tive invasive breast tumors. Furthermore, a shorter patient
disease-free and overall survival in P-cadherin-positive invasive
carcinomas was found using the statistical univariate analysis
done.
The phenotype acquired by this specific subset of tumors is
actually classified as myoepithelial/basal-like, which means the
acquisition of molecules frequently restricted to the myoepi-
thelia of normal breast tissue and loss of the ones expressed by
epithelial cells (35). These characteristics have indeed been
already associated with poor patient survival (35), confirming
that P-cadherin is one of the proteins related to biological
aggressiveness in breast carcinomas. In a recent report from our
group regarding the involvement of P-cadherin in cell invasion,
we have shown that this molecule has an effective proinvasive
activity in the MCF-7/AZ breast cancer cell line, through its
interaction with signaling proteins bound to the juxtamem-
brane domain (13). In a way, these results give an explanation
as to why P-cadherin is correlated with poor prognosis in breast
cancer patients. Accordingly, Taniuchi et al. also showed that
overexpressed P-cadherin/CDH3 promotes the motility of
pancreatic cancer cells by its interaction with p120ctn and
consequent activation of Rho-family GTPases (36). Based on
these results, the blocking of P-cadherin activity, or its
associated signaling, could probably be a novel therapeutic
approach for treatment of aggressive breast carcinomas.
We have already found a direct link between P-cadherin
expression and the lack of ER-a signaling in breast cancer cells,
showing that P-cadherin expression depends on an estrogen-
independent cell environment (13). Additionally, genetic or
epigenetic alterations in the P-cadherin gene is likely to regulate
the behavior of neoplastic cells as compared with that of
normal epithelial cells: cell-cell interactions may be changed,
leading to modified intercellular communication and, conse-
quently, altered intracellular signaling (37).
DNA methylation of promoter CpG islands has been
recognized as an important mechanism for regulation of gene
expression and transcriptional modification in mammals.
Although considerable work has been done on the epigenetic
control of tumor suppressor genes, little is known about the
potential role of promoter CpG demethylation in the activation
of oncogenes (32).
The present study showed a statistically significant correlation
between the methylation patterns of the CDH3 promoter region
of P-cadherin and its aberrant protein expression levels in breast
carcinomas. This methylation status of the DNA chromatin in
P-cadherin promoter region might play a role in the ability of
transcription factors to bind to the transcription start site, thus
regulating mRNA transcription, and consequently its protein
expression. Our results are supported by Jarrard and collabo-
rators’ data in prostate cancer cell lines (14). They showed that
CDH3 promoter methylation occurs in P-cadherin-negative cell
lines, but not in cell lines expressing this gene, and showed a
complete ablation of P-cadherin transcriptional activity when
methylation was present to any extent within the GC-rich
promoter region. This was also described in a recent study done
in melanoma cell lines (28), and is in keeping with reports on the
role of promoter methylation for transcriptional regulation of
tissue-specific genes (38). Moreover, the treatment of an
extensive culture of MCF-7/AZ breast cancer cell line with
5-Aza-2V -deoxycytidine demethylating agent induced the ex-
pression levels of P-cadherin mRNA and protein. These results
provided clear evidence that the observed correlation in vivo is
backed up by experimental in vitro data.
In contrast with our results, these same authors have reported
the absence of a correlation between in vivo P-cadherin
expression in prostate adenocarcinomas and the methylation
status of the CDH3 promoter (14). In prostate tissue, P-cadherin
is strongly expressed on basal epithelial cells and is completely
negative in luminal epithelial cells. However, in contrast with
breast cancer, this protein was absent in the prostate cancers
analyzed in this study. Additionally, the methylation status of a
P-cadherin CpG island was examined in 12 normal and matched
primary prostate cancers, using methylation-sensitive enzymes.
Although all the restriction sites analyzed were found to be
unmethylated in P-cadherin-positive normal tissues, no detect-
able methylation was shown in any tumor sample, showing no
correlation with the absence of P-cadherin expression (14). In
our opinion, the conflicting results obtained by these authors can
be explained by two reasons: (a) the number of cases that were
studied and (b) the distinct methodology that was used. Also in
our series, we obtained cases that did not show correlation
between the promoter methylation status and the protein
expression: 29% of the P-cadherin-negative cases showed
unmethylation pattern, and 35% of the positive cases were
methylated. However, using statistical analysis in a large tumor
series, we were able to find a significant correlation between
P-cadherin expression and gene hypomethylation. Statistics
using only 12 cases cannot be representative of the methylation
process as a regulator mechanism occurring in cancer cells.
Besides, these authors claim that the normal prostate tissue is
completely unmethylated for the P-cadherin gene in all the
restriction sites analyzed. Because normal tissue includes basal
P-cadherin-positive cells as well as luminal P-cadherin-negative
cells, it was expected to find both methylated and unmethylated
alleles in these samples. Therefore, we used methylation-specific
PCR assays in order to analyze larger DNA fragments, and also
microdissected our samples to get more homogenous cell
populations.
Furthermore, supporting our hypothesis, the laser-micro-
dissected normal breast epithelia showed complete methylation
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of the CDH3 promoter region in the five cases studied,
suggesting that P-cadherin protein expression is repressed in
normal epithelial cells by this specific molecular mechanism.
Based on these results, we can suggest that, during breast
carcinogenesis, progressive hypomethylation of CDH3 alleles
occurs, which induces its expression in some mammary
carcinomas, where its functional activity induces cancer cell
invasion and motility (13, 36). This progressive CDH3
promoter hypomethylation is clearly seen in cases presenting
partial methylation, which were still negative for P-cadherin
expression like the normal epithelial cells.
Cancer-associated DNA hypomethylation is as prevalent as
cancer-linked hypermethylation, although its biological
significance in carcinogenesis is less understood. There are
several examples of other tumor-overexpressed genes, which
become promoter-hypomethylated during carcinogenesis,
supporting the data observed within CDH3 . The cyclin D2
gene is overexpressed in a subset of gastric carcinomas, and
Oshimo et al. have shown that DNA hypomethylation is a
mechanism underlying the increased expression of cyclin D2
in cancer cells and that its progressive demethylation may be
involved in the development and progression of gastric
carcinoma (32). Also, the melanoma antigen (MAGE)–
encoding genes are expressed in various tumor types via
demethylation of their promoter CpG islands (39), which are
silent in all nonneoplastic tissues except for the testis and
placenta. Honda et al. have found that MAGE-A1 and -A3
demethylation occurs during progressive stages of gastric
cancer, and tended to be associated with a worse patient
prognosis (40). Also in breast cancer, urokinase-type plasmin-
ogen activator, which is only expressed by highly invasive
cancer cells and has been implicated in tumor motility,
invasion, and angiogenesis, was also found to be the result of
hypomethylation of its codifying gene (41–43).
In conclusion, although there is just a small number of genes
that have been shown to be transcriptionally activated by DNA
demethylation, in comparison with the list of tumor suppressor
genes that are silenced by hypermethylation in cancer cells, all
these studies are consistent with the hypothesis that hypome-
thylation of critical genes plays a role in cancer invasion and
metastasis. Based on this, the methylation inhibition of these
genes, like urokinase-type plasminogen activator and
P-cadherin in breast cancer, can be used as a novel therapeutic
approach to silence their expression and, consequently, to
block tumor progression into the aggressive and metastatic
stages of the disease.
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